The price of Surgery Partners Inc (NASDAQ: SGRY) closed at $30.20 in the last session, down -8.60% from day before closing price of $33.04. In other words, the price has decreased by -$2.84 from its previous closing price. On the day, 4147737 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at SGRY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.81. For the most recent quarter (mrq), Quick Ratio is recorded 1.61 and its Current Ratio is at 1.71. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.89.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on November 14, 2023, Upgraded its rating to Outperform and sets its target price to $35 from $39 previously.
On June 02, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $42 to $45.
On May 12, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $48.Mizuho initiated its Buy rating on May 12, 2023, with a $48 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 14 when Burkhalter Danielle sold 192 shares for $33.42 per share. The transaction valued at 6,417 led to the insider holds 30,444 shares of the business.
TAPARO ANTHONY sold 1,100 shares of SGRY for $36,740 on Feb 13. The Chief Growth Officer now owns 91,315 shares after completing the transaction at $33.40 per share. On Feb 12, another insider, Evans Jason Eric, who serves as the Chief Executive Officer of the company, sold 5,780 shares for $35.08 each. As a result, the insider received 202,762 and left with 419,118 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 3.82B and an Enterprise Value of 6.56B. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.48 while its Price-to-Book (P/B) ratio in mrq is 1.91. Its current Enterprise Value per Revenue stands at 2.42 whereas that against EBITDA is 15.83.
Stock Price History:
Over the past 52 weeks, SGRY has reached a high of $45.79, while it has fallen to a 52-week low of $22.05. The 50-Day Moving Average of the stock is 32.51, while the 200-Day Moving Average is calculated to be 33.65.
Shares Statistics:
According to the various share statistics, SGRY traded on average about 907.13K shares per day over the past 3-months and 850.48k shares per day over the past 10 days. A total of 125.96M shares are outstanding, with a floating share count of 81.01M. Insiders hold about 39.76% of the company’s shares, while institutions hold 62.23% stake in the company. Shares short for SGRY as of Jan 31, 2024 were 7.78M with a Short Ratio of 8.58, compared to 6.54M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.15% and a Short% of Float of 16.01%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.38 for the current quarter, with a high estimate of $0.42 and a low estimate of $0.32, while EPS last year was $0.27. The consensus estimate for the next quarter is $0.12, with high estimates of $0.25 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.96 and $0.87 for the fiscal current year, implying an average EPS of $0.93. EPS for the following year is $1.07, with 10 analysts recommending between $1.78 and $0.85.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $741.51M. It ranges from a high estimate of $743.62M to a low estimate of $737.26M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $707.1M, an estimated increase of 4.90% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $715.47M, an increase of 7.40% over than the figure of $4.90% in the same quarter last year. There is a high estimate of $731.77M for the next quarter, whereas the lowest estimate is $701.22M.
A total of 10 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $2.75B, while the lowest revenue estimate was $2.75B, resulting in an average revenue estimate of $2.75B. In the same quarter a year ago, actual revenue was $2.54B, up 8.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $2.99B in the next fiscal year. The high estimate is $3.02B and the low estimate is $2.97B. The average revenue growth estimate for next year is up 8.90% from the average revenue estimate for this year.
